GlassScriptPhysician profile
Robert J Hughes
NPI 1407842248
$4,257.05
in general payments reported to CMS, 2019-2025
28 companies · $624 in 2025
The $624 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $618 · 2021: $510 · 2022: $694 · 2023: $530 · 2024: $472 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,626.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $555.39 | 2019-2025 | Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $474.49 | 2020-2025 | Nucala, Trelegy Ellipta |
| Intersect Ent, INC. | $331.90 | 2020-2022 | |
| Harmony Biosciences LLC | $328.84 | 2022-2025 | Wakix |
| Optinose US, INC. | $292.14 | 2019-2024 | |
| Acclarent, INC | $279.06 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $259.10 | 2020-2025 | |
| Genzyme Corporation | $212.37 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.00 | 2020-2025 | Cuvitru, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $159.01 | 2019-2024 | Dupixent |
| Amgen INC. | $139.78 | 2022-2025 | Tavneos |
| Medtronic, INC. | $138.25 | 2022 | |
| Novartis Pharmaceuticals Corporation | $126.89 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $125.00 | 2025 | Nuzyra |
| Csl Behring | $116.20 | 2021-2025 | Hizentra, Andembry |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $111.22 | 2025 | Nuplazid |
| Kaleo, INC. | $72.12 | 2019-2022 | |
| Alk-Abello, INC | $55.47 | 2019-2021 | |
| Pfizer INC. | $50.00 | 2019 | |
| Grifols USA, LLC | $46.31 | 2019-2024 | Xembify |
| Merck Sharp & Dohme LLC | $30.10 | 2021-2023 | |
| Pharming Healthcare, INC. | $28.25 | 2023 | Ruconest |
| Avadel Cns Pharmaceuticals, LLC | $27.91 | 2024 | Lumryz |
| Axsome Therapeutics, INC. | $25.53 | 2022 | |
| Aerin Medical INC. | $21.69 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $20.56 | 2025 | Neffy |
| Blueprint Medicines Corporation | $13.46 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.